Sangheun Lee
Kwandong University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sangheun Lee.
Journal of Viral Hepatitis | 2017
Sangheun Lee; S.H. Ahn; Kyu Sik Jung; D.Y. Kim; Bun Kim; Soo-Ki Kim; Oidov Baatarkhuu; Hye Jin Ku; Kwang Hyub Han; J.Y. Park
We compared the viral suppressive efficacy of tenofovir disoproxil fumarate (TDF) mono‐rescue therapy (TDF group) and TDF plus entecavir (ETV) combination‐rescue therapy (TDF + ETV group) in chronic hepatitis B (CHB) patients with lamivudine resistance and entecavir resistance. One hundred and thirty‐three CHB patients with lamivudine and entecavir resistance were investigated. Ninety‐six patients were treated with TDF and 37 with TDF + ETV for at least 6 months. We compared the virologic response rate (HBV DNA level <20 IU/mL) between the two groups and identified the predictive factors of treatment outcome. There were no significant differences between the two groups in demographic characteristics. Up to 24 months [median: 18 (range 6‐24) months], 85.4% and 89.2% of the TDF group and TDF + ETV group, respectively, achieved a virologic response (P=.068). Only the HBV DNA level at baseline was significantly associated with a virologic response in the multivariate analysis. In a subanalysis of patients with HBV DNA levels ≥4 log (IU/mL) at baseline, a higher proportion of patients in the TDF + ETV group than the TDF group achieved a virologic response (92.9% vs 68.3%; P<.001), while 90% of patients with HBV DNA (IU/mL) levels <4 log in all both TDF and TDF + ETV groups achieved a virologic response. TDF mono‐rescue therapy is a reasonable option in patients with lamivudine resistance and entecavir resistance. However, the combination strategy should be considered in patients with high baseline HBV DNA levels.
Journal of Epidemiology | 2015
Ja Sung Choi; Ki Jun Han; Sangheun Lee; Song Wook Chun; Dae Jung Kim; Hyeon Chang Kim; Hee Man Kim
Background Metabolic syndrome has clinical implications for chronic liver disease, but the relationship between chronic hepatitis B and metabolic syndrome remains unclear. The aim of this study was to determine whether hepatitis B surface antigen (HBsAg) positivity is associated with metabolic syndrome. Methods Data were obtained from the Third Korean National Health and Nutrition Examination Survey (KNHANES). Participant sera were tested for HBsAg. Metabolic syndrome was defined according to the modified National Cholesterol Education Program Adult Treatment Panel III guidelines for Koreans. Results Of the 5108 participants, 209 (4.1%) tested positive for HBsAg, and 1364 (26.7%) were diagnosed with metabolic syndrome. The prevalence of metabolic syndrome was 23.4% in HBsAg-positive men, 31.5% in HBsAg-negative men, 18.6% in HBsAg-positive women, and 23.7% in HBsAg-negative women. After adjusting for multiple factors, male participants who tested positive for serum HBsAg had an odds ratio of 0.612 (95% confidence interval [CI] 0.375–0.998) for metabolic syndrome and an odds ratio of 0.631 (95% CI 0.404–0.986) for elevated triglycerides. Women who tested positive for serum HBsAg had an odds ratio of 0.343 (95% CI 0.170–0.693) for elevated triglycerides. Conclusions Positive results for serum HBsAg are inversely associated with metabolic syndrome in men and with elevated triglycerides in men and women. This suggests that elevated triglycerides may contribute to the inverse association between HBsAg and metabolic syndrome.
Gut and Liver | 2015
Sangheun Lee; Jun Yong Park; Kijun Song; Do Young Kim; Beom Kyung Kim; Seung Up Kim; Hye Jin Ku; Kwang Hyub Han; Sang Hoon Ahn
Background/Aims The aim of this study was to evaluate the estimated glomerular filtration rate (eGFR) during telbivudine (LdT) versus entecavir (ETV) treatment in chronic hepatitis B (CHB) patients with underlying comorbidities such as diabetes mellitus (DM), hypertension, and cirrhosis. Methods From 2010 to 2012, 116 CHB patients treated with LdT and 578 treated with ETV were compared in this real-practice cohort. The mean changes in eGFR (Modification of Diet in Renal Disease [MDRD] formula) from baseline to months 6, 12, and 18 were analyzed using a linear mixed model. Results In LdT-treated patients, the mean eGFR increased by 7.6% at month 18 compared with the eGFR at baseline (MDRD formula in mL/min/1.73 m2). However, in ETV-treated patients, the mean eGFR decreased by 4.1% at month 18 compared with the eGFR at baseline. In the LdT-treated patients with DM, hypertension, cirrhosis or low eGFR <90 mL/min/1.73 m2, the mean eGFR showed a steady improvement, whereas the mean eGFR was reduced in the same subgroups of ETV-treated patients. Conclusions The eGFR gradually increased over time during LdT treatment, especially in patients with mild abnormal eGFR at baseline, and in those with DM, hypertension, and cirrhosis, whereas a reduction in eGFR was seen with ETV treatment.
Journal of Korean Medical Science | 2011
Sangheun Lee; In Tae Kim; Hyung Bok Park; Yu Kyung Hyun; Yoon Ji Kim; Sun Ok Song; Hyeong-Jin Kim
Inflammation is thought to play a role in the pathogenesis of major adverse cardiovascular events (MACE). It has been suggested that the measurement of markers of inflammation may aid in predicting the risk of such events. Here, the relationship between high-sensitivity C-reactive protein (hs-CRP) levels and MACE in Korean patients with type 2 diabetes is assessed. A retrospective cohort study was conducted as a follow-up among 1,558 patients with type 2 diabetes and without cardiovascular diseases over a mean period of 55.5 months. A Cox proportional-hazards model was used to determine whether increased hs-CRP levels are useful as a predictor for future MACE. The hazard ratio of MACE was 1.77 (95% CI; 1.16-2.71) in subjects who had the highest hs-CRP levels (> 0.21 mg/dL) compared to subjects who had the lowest hs-CRP levels (< 0.08 mg/dL), after adjusting for age, regular physical activity, current smoking, and duration of diabetes. The present results indicate that high hs-CRP levels can act as a predictor for the MACE occurrence in Korean patients with type 2 diabetes.
Yonsei Medical Journal | 2011
Seung Won Lee; Sangheun Lee; Se Hwa Kim; Tae Ho Kim; Byung Soo Kang; Seung Hoon Yoo; Min Kyung Lee; Won Jun Koh; Won Sik Kang; Hyeong Jin Kim
Purpose The aim of this study was to identify the most precise and clinically practicable parameters that predict future oral hypoglycemic agent (OHA) failure in patients with type 2 diabetes, and to determine whether these parameters are valuable in various subgroups. Materials and Methods We took fasting blood samples from 231 patients for laboratory data and standard breakfast tests for evaluation of pancreatic beta-cell function. Hemoglobin A1c (HbA1c) levels were tested, and we collected data related to hypoglycemic medications one year from the start date of the study. Results Fasting C-peptide, postprandial insulin and C-peptide, the difference between fasting and postprandial insulin, fasting beta-cell responsiveness (M0), postprandial beta-cell responsiveness (M1), and homeostasis model assessment-beta (HOMA-B) levels were significantly higher in those with OHA response than in those with OHA failure. The area under the curve (AUC) of the receiver operating characteristic (ROC) measured with postprandial C-peptide to predict future OHA failure was 0.720, and the predictive power for future OHA failure was the highest of the variable parameters. Fasting and postprandial C-peptide, M0, and M1 levels were the only differences between those with OHA response and those with OHA failure among diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes. Conclusion In conclusion, postprandial C-peptide was most useful in predicting future OHA failure in type 2 diabetic subjects. However, these parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
World Journal of Gastroenterology | 2013
Jae Hee Cho; Hee Man Kim; Sangheun Lee; Yu Jin Kim; Ki Jun Han; Hyeon Geun Cho; Si Young Song
AIMnTo investigate the feasibility of a single-use endoscopy as an alternative procedure to nasogastric lavage in patients with acute gastrointestinal (GI) bleeding.nnnMETHODSnPatients who presented with hematemesis, melena or hematochezia were enrolled in this study. EG scan™ and conventional esophagogastroduodenoscopy (EGD) were subsequently performed. Active bleeding was defined as blood in the stomach, and inactive bleeding was defined as coffee ground clots and clear fluid in the stomach. The findings were recorded and compared.nnnRESULTSnBetween January and March, 2011, 13 patients that presented with hematemesis (n = 4), melena (n = 6), or bleeding from a previous nasogastric feeding tube (n = 3), were enrolled in this study. In 12 patients with upper GI bleeding, the EG scan device revealed that 7 patients had active bleeding and 5 patients had inactive bleeding, whereas conventional EGD revealed that 8 patients had active bleeding and 4 patients had inactive bleeding. The sensitivity and specificity of the EG scan device was 87.5% and 100% for active bleeding, with conventional EGD serving as a reference. No complication were reported during the EG scan procedures.nnnCONCLUSIONnThe EG scan is a feasible device for screening acute upper GI bleeding. It may replace nasogastric lavage for the evaluation of acute upper GI bleeding.
Hepato-gastroenterology | 2013
Sangheun Lee; Chang Mo Moon; Yu Jin Kim; Jae Hee Cho; Hee Man Kim; Ki Joon Han; Hyeon Geun Cho; Seung Won Lee; Ha Eun Oh; Ji Sun Song; Sang Yeop Yi; Nak Hoon Son
BACKGROUND/AIMSnNarrow band imaging (NBI) is an optical endoscopic technique for predicting polyp histology during colonoscopy. However, it has not been elucidated the impact of polyp characteristics on the diagnostic capabilities of NBI. We aimed to evaluate which polyp characteristics can influence the diagnostic accuracy of NBI for discriminating neoplastic from non-neoplastic colorectal polyps.nnnMETHODOLOGYnA total of 232 colorectal polyps from 134 patients undergoing screening or surveillance colonoscopy were retrospectively analyzed. White light imaging (WLI) and NBI images of polyps were assessed by two experienced endoscopists and two trainees and then compared with histopathology.nnnRESULTSnWhen classified according to polyp morphology, NBI as well as WLI had a significantly lower sensitivity and diagnostic accuracy for non-polypoid lesions than for polypoid lesions in both experienced and trainee groups. In contrast, the specificity of NBI and WLI for non-polypoid lesions was higher than that for polpyoid lesions. As for polyp size, the diagnostic accuracy of NBI for polyps ≤5mm was significantly lower than for polyps of 6 to 9mm or ≤10mm in the experienced group.nnnCONCLUSIONSnNBI had a significantly lower diagnostic accuracy for predicting polyp histology in non-polypoid or diminutive colorectal lesions.
Hepato-gastroenterology | 2013
Park Jh; Kim Tn; Sangheun Lee
T201500319.pdf | 2015
Ja Sung Choi; Ki Jun Han; Hee Man Kim; Hyeon Chang Kim; Dae Jung Kim; Song Wook Chun; Sangheun Lee
Hepato-gastroenterology | 2014
Sangheun Lee; Jun C.hul Park; Hyuk Lee; Yong C.han Lee; Sung K.wan Shin; Woo Jin Hyung; Hoon Noh; Choong B.ai Kim; Hyun Ki Kim; Dae R.yong Kang; Sang K.il Lee